NCT04023331 - 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

January 24, 2025

Study Completion Date

March 25, 2025

Conditions

NeuroblastomaRelapsed NeuroblastomaRefractory Neuroblastoma

Interventions

DRUG

67Cu-SARTATE

67Cu-labelled MeCOSar-Tyr3-octreotate

DRUG

64Cu-SARTATE

64Cu-labelled MeCOSar-Tyr3-octreotate

Trial Locations (8)

Memorial Sloan Kettering Cancer Center, New York

Medical University of South Carolina, Charleston

Cincinnati Children's Hospital Medical Centre, Cincinnati

University of Wisconsin, Madison

Washington University School of Medicine, St Louis

University of Texas Southwestern Medical Centre, Dallas

MD Anderson Cancer Center, Houston

Phoenix Children's Hospital, Phoenix